论文信息 - Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease. - 字舞流文

Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease.

T. Laidlaw | J. Levy | K. Buchheit

[1] G. Milne,et al. Inflammatory Heterogeneity in Aspirin Exacerbated Respiratory Disease. , 2020, The Journal of allergy and clinical immunology.

[2] A. Shalek,et al. IL-5Rα marks nasal polyp IgG4 and IgE-expressing cells in aspirin-exacerbated respiratory disease. , 2020, The Journal of allergy and clinical immunology.

[3] J. Mullol,et al. Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD. , 2019, The journal of allergy and clinical immunology. In practice.

[4] R. Panettieri,et al. Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size , 2018, The Laryngoscope.

[5] Andrew A. White,et al. Aspirin-Exacerbated Respiratory Disease. , 2018, The New England journal of medicine.

[6] Alex K. Shalek,et al. Allergic inflammatory memory in human respiratory epithelial progenitor cells , 2018, Nature.

[7] Y. Hasegawa,et al. Omalizumab reduces cysteinyl leukotriene and 9α,11β-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease. , 2016, The Journal of allergy and clinical immunology.